What is tucatinib?

Tucatinib is a cancer drug used to treat breast cancer that is locally advanced or metastatic (has spread to other parts of the body), and breast cancer that is HER2-positive, meaning that cancer cells produce a protein called HER on their surface. 2. To stimulate cancer growth, it can also be used in combination with two other drugs (capecitabine and trastuzumab), such as in combination with trastuzumab to treat adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer after at least 2 other HER2-positive cancer treatments have been tried.

The active ingredient in tucatinib, tucatinib, belongs to a class of cancer drugs called tyrosine kinase inhibitors. It attaches to the HER2 protein on cancer cells, thus blocking its action. Because HER2 helps cancer cells grow and divide, blocking it helps control cancer growth by stopping these cells from growing and causing them to die. Survival improved with tucatinib in a group of patients who had few other options.

It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals. The price of the European version of tucatinib original drug sold overseas is around RMB 72,000 (the price may fluctuate due to exchange rates), which is expensive. There are also generic drugs of tucatinib produced in other countries. The price of Tucatinib produced by a Lao pharmaceutical factory is around 6,400 yuan (the price may fluctuate due to the exchange rate). The price is much cheaper than the original drug, and the ingredients of foreign generic drugs are basically the same as the original drug.